<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391468</url>
  </required_header>
  <id_info>
    <org_study_id>DMR-99-IRB-308</org_study_id>
    <nct_id>NCT01391468</nct_id>
  </id_info>
  <brief_title>Beneficial Effect of Probiotics on Chronic Kidney Disease</brief_title>
  <official_title>Beneficial Effect of Probiotics on Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blinded placebo control studies are performed in Chronic Kidney
      Disease (CKD) patients. After informed consent, intervention group receives probiotics
      containing 109 CFU B. bifidum, B.catenulatum, B. longum, and L.plantarm), while placebo group
      receives corn starch. In the first year the investigators examine the 60 peritoneal dialysis
      (PD) patients, in the second year the investigators do the 60 hemodialysis (HD) patients, and
      in the third year the investigators do the 60 stage 3 and 4 CKD patients. Primary endpoint is
      cardiovascular event, gastrointestinal symptoms, peritonitis in PD patients, and progression
      of stage 3 and 4 CKD. Values are compared between the groups by unpaired t test. X2 testis
      used to compare proportions between the groups. Relative risk and the number needed to treat,
      both with 95% CI, are used to describe the treatment effect of probiotics. A p value less
      than 0•05 is regarded as statistically significant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is a global health issue that has a substantial impact on
      affected individuals. The prognosis of dialysis patients is poor with 30 to 50 percent 5 year
      survival in nondiabetic patients and 25 percent in diabetics. Cardiovascular disease accounts
      for approximately half of death of dialysis patients Chronic inflammation, which is widely
      seen in long-term dialysis patients, is associated with malnutrition, atherosclerosis and an
      increased mortality risk. Inflammatory markers such as C-reactive protein (CRP),IL-6, Il-18
      and TNF-α, are elevated in dialysis and can predict cardiovascular event and all-cause
      mortality.

      Probiotics are microorganisms that have beneficial properties for the host. Three described
      benefits include suppression of growth or epithelial binding/invasion by pathogenic bacteria,
      improvement of intestinal barrier function and modulation the immune systems.

      Several probiotics preparations induce protective cytokines, including IL-10, and suppress
      proinflammatory cytokines, such as TNF-α and IL-6. Intestinal microflora is deranged in
      hemodialysis (HD) patients as an increase in aerobic bacteria such as E. coli and a decrease
      in anaerobic bacteria such as Bifidobacterium. One study reported that oral administration of
      ifidobacterium longum in a gastroresistant seamless capsule decreases the the pre-HD serum
      levels of homocysteine and indoxyl sulfate. Another small-scale study from Japan showed that
      synbiotics containing lactobacilli and can reduce serum level of p-Cresol in HD patients.
      High-serum p-cresyl sulfate and indoxyl sulfate levels were associated with renal
      progression. Serum concentrations of p-cresol are independently associated with overall
      mortality and cardiovascular disease in HD patients. The aim of the study is 1. to evaluate
      the difference of intestinal microflora between CKD patients and healthy controls; 2. to
      evaluate whether the investigators can reduce cardiovascular events in CKD patients, and
      peritonitis in peritoneal dialysis (PD) patients, retard the progression of stage 3 and 4 CKD
      patients, and decrease circulating inflammatory markers(CRP, IL-6,IL-18, TNF-α), indoxyl
      sulfate, p-cresol and homocysteine after probiotics treatment.

      Randomized double blinded placebo control studies are performed in CKD patients. After
      informed consent, intervention group receives probiotics containing 109 CFU B. bifidum,
      B.catenulatum, B. longum, and L.plantarm), while placebo group receives corn starch. In the
      first year the investigators examine the 60 PD patients, in the second year the investigators
      do the 60 HD patients,and in the third year the investigators do the 60 stage 3 and 4 CKD
      patients. Primary endpoint is cardiovascular event, gastrointestinal symptoms, peritonitis in
      PD patients, and progression of stage 3 and 4 CKD. Values are compared between the groups by
      unpaired t test. X2 testis used to compare proportions between the groups. Relative risk and
      the number needed to treat, both with 95% CI, are used to describe the treatment effect of
      probiotics. A p value less than 0·05 is regarded as statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Occurrence of Cardiovascular Event and Peritonitis Events</measure>
    <time_frame>6 month follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Gastrointestinal Symptoms at 6 Months</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>The change in gastrointestinal symptom rating scale (min and maximum scores 0-45) after treatment. The total score is reported. The higher scale represents a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>cornstarch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cornstarch</intervention_name>
    <description>placebo will be given in 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. receiving peritoneal dialysis for more than 3 months, at least 18 years of age, and
             GFR &lt; 15 ml/min.

          2. receiving hemodialysis dialysis for more than 3 months, at least 18 years of age, and
             GFR &lt; 15 ml/min.

          3. Stage 3 and 4 CKD patients

        Exclusion Criteria:

          -  active infectious conditions within the last 30 days,

          -  pregnancy for female,

          -  autoimmune disease e.g. SLE.,

          -  cardiovascular events before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Kuan Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>413</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <results_first_submitted>February 2, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2015</results_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>I-Kuan Wang</investigator_full_name>
    <investigator_title>China Medical University Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Cornstarch: placebo will be given in 6 months</description>
        </group>
        <group group_id="P2">
          <title>Probiotics</title>
          <description>Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Cornstarch: placebo will be given in 6 months</description>
        </group>
        <group group_id="B2">
          <title>Probiotics</title>
          <description>Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-6</title>
          <description>inflammatory cytokine</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.27" spread="12.78"/>
                    <measurement group_id="B2" value="6.55" spread="10.72"/>
                    <measurement group_id="B3" value="5.90" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Occurrence of Cardiovascular Event and Peritonitis Events</title>
        <time_frame>6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Cornstarch: placebo will be given in 6 months</description>
          </group>
          <group group_id="O2">
            <title>Probiotics</title>
            <description>Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
          </group>
        </group_list>
        <measure>
          <title>the Occurrence of Cardiovascular Event and Peritonitis Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritonitis event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Gastrointestinal Symptoms at 6 Months</title>
        <description>The change in gastrointestinal symptom rating scale (min and maximum scores 0-45) after treatment. The total score is reported. The higher scale represents a worse outcome.</description>
        <time_frame>6 months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>cornstarch
Cornstarch: placebo will be given in 6 months</description>
          </group>
          <group group_id="O2">
            <title>Probiotics</title>
            <description>probiotics
Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Gastrointestinal Symptoms at 6 Months</title>
          <description>The change in gastrointestinal symptom rating scale (min and maximum scores 0-45) after treatment. The total score is reported. The higher scale represents a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="5"/>
                    <measurement group_id="O2" value="-1.38" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change of Serum Endotoxin Level at 6 Months</title>
        <description>endotoxin is a marker of inflammation in chronic kidney disease patients</description>
        <time_frame>6 months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotics</title>
            <description>probiotics
Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placeo group received maltodextrin for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Endotoxin Level at 6 Months</title>
          <description>endotoxin is a marker of inflammation in chronic kidney disease patients</description>
          <units>EU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.61"/>
                    <measurement group_id="O2" value="0.84" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <p_value_desc>Only the probiotics group arrived at the reported p-value after 6 months</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change of Serum IL-10 Level at 6 Months</title>
        <description>IL-10 is an anti-inflammatory cytokine; The change of serum IL-10 level at 6 months was measured</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotics</title>
            <description>probiotics
Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Plabeco group received maltodextrin for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum IL-10 Level at 6 Months</title>
          <description>IL-10 is an anti-inflammatory cytokine; The change of serum IL-10 level at 6 months was measured</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="6.37"/>
                    <measurement group_id="O2" value="-2.09" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0099</p_value>
            <p_value_desc>Only the probiotics group arrived at the reported p-value after 6 months</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Probiotics</title>
          <description>Probiotics: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Cornstarch: placebo will be given in 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>II-Kuan Wang</name_or_title>
      <organization>China Medical University</organization>
      <phone>88975681050</phone>
      <email>ikwang@seed.net.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

